Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Period	TotalRevenue
2015-12-31	$5.52M
2016-12-31	$4.00M
2017-12-31	$2.67M
2018-12-31	$1.67M
2019-12-31	N/A
2020-12-31	$310.25K
2021-12-31	$244.90K
2022-12-31	$2.55M
2023-12-31	$25.18M
2024-12-31	$22.27M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CAPR	$31.35	-1.94%	0.43M
3
4
5

Capricor Therapeutics Inc. (CAPR) Revenue History

Revenue Data

Get Capricor Therapeutics Inc. Data in Excel

More CAPR Financial Data